ライフサイエンスコーパス: ST elevation myocardial infarction

1 unct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction).

2 -elevation myocardial infarction and 45% non-ST-elevation myocardial infarction).

3 ncluded patients with unstable angina or non-ST elevation myocardial infarction.

4 ents (58+/-11 years) were enrolled after non-ST elevation myocardial infarction.

5 e therapy with fibrinolysis in patients with ST-elevation myocardial infarction.

6 diology for treatment of unstable angina/non-ST-elevation myocardial infarction.

7 ents > or =65 years of age hospitalized with ST-elevation myocardial infarction.

8 a pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction.

9 an antithrombotic agent for the treatment of ST-elevation myocardial infarction.

10 non ST-elevation myocardial infarction, and ST-elevation myocardial infarction.

11 imary percutaneous coronary intervention for ST-elevation myocardial infarction.

12 al outcomes in a population of patients with ST-elevation myocardial infarction.

13 y in the setting of thrombolytic therapy for ST-elevation myocardial infarction.

14 s coronary intervention with stenting during ST-elevation myocardial infarction.

15 nce of the clinical inflammatory response in ST-elevation myocardial infarction.

16 female population, frequently presenting as ST-elevation myocardial infarction.

17 emporary medical therapy and were limited to ST-elevation myocardial infarction.

18 a hypercoagulable state 3 years ago after an ST-elevation myocardial infarction.

19 entary biomarkers of biomechanical strain in ST-elevation myocardial infarction.

20 safer than 325 mg for the acute treatment of ST-elevation myocardial infarction.

21 articipants were patients undergoing PCI for ST-elevation myocardial infarction (11.6%), non-ST-eleva

22 ST-elevation myocardial infarction, 316 non-ST-elevation myocardial infarction, 218 unstable angina,

23 cks [TIA]); 856 (42%) coronary vascular (159 ST-elevation myocardial infarction, 316 non-ST-elevation

24 Patients included 76716 with ST-elevation myocardial infarction, 35527 with unstable

25 to what has been observed in the setting of ST-elevation myocardial infarction, abnormal tissue leve

26 ients were excluded if they presented with a ST-elevation myocardial infarction, acute stroke, or tra

27 ith >12 h from onset of chest pain and acute ST elevation myocardial infarction (AMI) who received ei

28 r mortality for women compared with men with ST elevation myocardial infarctions and higher rates of

29 on in acute coronary syndromes patients (55% ST-elevation myocardial infarction and 45% non-ST-elevat

30 PRIMULTI study (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disea

31 sented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned

32 ST-elevation myocardial infarction and sinus venous trac

33 ients randomized, 441 patients had confirmed ST-elevation-myocardial infarction and underwent primary

34 nts receiving fibrinolytic therapy for acute ST elevation myocardial infarction, and ST resolution is

35 l infarction, 35527 with unstable angina/non-ST-elevation myocardial infarction, and 10215 undergoing

36 m of disease, including unstable angina, non ST-elevation myocardial infarction, and ST-elevation myo

37 sive strategy, acute coronary syndromes, non-ST-elevation myocardial infarction, and unstable angina.

38 acological reperfusion therapy in women with ST-elevation myocardial infarction are of particular int

39 The adjusted hazard of death or ST-elevation myocardial infarction at 2 years was simila

40 gina, stable angina, and unstable angina/non-ST-elevation myocardial infarction between January 1, 20

41 Supplemental oxygen therapy in patients with ST-elevation-myocardial infarction but without hypoxia m

42 he AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction) cardiac magnetic res

43 of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction [DANAMI-3]; NCT014354

44 en is commonly administered to patients with ST-elevation-myocardial infarction despite previous stud

45 Study patients presented with an acute ST-elevation myocardial infarction diagnosed by prehospi

46 with no supplemental oxygen in patients with ST-elevation-myocardial infarction diagnosed on paramedi

47 of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction) did not show any imp

48 We evaluated 3,362 patients with ST elevation myocardial infarction enrolled in various P

49 % vs 8.4%, P =.98 ), but a small decrease in ST-elevation myocardial infarction existed (2.4% vs 2.0%

50 iding Management to Optimize Outcomes in Non-ST-Elevation Myocardial Infarction (FAMOUS-NSTEMI) study

51 French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 accord

52 French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 (n=367

53 onal characteristics, admission diagnosis of ST-elevation myocardial infarction, femoral access for a

54 asured ST2 at baseline in 1239 patients with ST-elevation myocardial infarction from the CLopidogrel

55 A significant proportion of patients with ST-elevation myocardial infarction have persistent impai

56 In ST-elevation myocardial infarction, high baseline ST2 le

57 onally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies a

58 Presentation was ST-elevation myocardial infarction in 49%.

59 l Infarction], TASTE [Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia], and

60 nary syndrome, although anemic patients with ST-elevation myocardial infarction may benefit from this

61 rtery reperfusion for the treatment of acute ST-elevation myocardial infarction (MI), morbidity and m

62 italization with an ACS (non-ST-elevation or ST-elevation myocardial infarction [MI]) at 868 sites in

63 In ST elevation myocardial infarction, new aggressive throm

64 (A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction [Non-STEMI] Undergoin

65 rkedly, particularly among patients with non-ST elevation myocardial infarction (NSTEMI).

66 nvasive strategy in unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) that were co

67 report a decline in mortality following non-ST-elevation myocardial infarction (NSTEMI).

68 ct of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction [NSTEMI] PATIENTS: On

69 range of 2 to 13 days, and 1 patient had an ST-elevation myocardial infarction on day 39 with eviden

70 Patients with ST-elevation myocardial infarction or previous myocardia

71 djusting for multiple comparisons, including ST-elevation myocardial infarction (OR, 0.99; 95% CI, 0.

72 ely to develop heart failure (P<0.0001), non-ST-elevation myocardial infarction (P=0.003), and AKI (P

73 ct of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction Patients: One Stage V

74 ST-elevation myocardial infarction than non-ST-elevation myocardial infarction patients (95.1% versu

75 ital quality-of-care programs recommend that ST-elevation myocardial infarction patients achieve a do

76 in-hospital LVEF assessment among 77 982 non-ST-elevation myocardial infarction patients and 50 863 S

77 and compared this group with 86 consecutive ST-elevation myocardial infarction patients from Septemb

78 on myocardial infarction patients and 50 863 ST-elevation myocardial infarction patients in Acute Cor

79 cted door-to-balloon time for 60 consecutive ST-elevation myocardial infarction patients undergoing e

80 time would further improve 30-day outcome in ST-elevation myocardial infarction patients undergoing p

81 Between January 2008 and December 2009, 266 ST-elevation myocardial infarction patients underwent pr

82 consecutively enrolled as group 1, while 293 ST-elevation myocardial infarction patients underwent pr

83 Unstable angina or non-ST-elevation myocardial infarction patients with increas

84 on (ExTRACT-TIMI) 25 study, which randomized ST-elevation myocardial infarction patients with planned

85 The thrombospondin-1 concentrations in ST-Elevation Myocardial Infarction patients with severe

86 ronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction patients), we compare

87 ersus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients.

88 In the presence of ST-elevation myocardial infarction, patients with succes

89 In TIMI 10B, 886 patients with acute ST-elevation myocardial infarction presenting within 12

90 f patients undergoing surgical treatment for ST-elevation myocardial infarction receive antifibrinoly

91 everal organ systems, but their relevance in ST elevation myocardial infarction (STEMI) is unknown.

92 sults at 1 year after thrombus aspiration in ST elevation myocardial infarction (STEMI).

93 Interhospital transfer of patients with ST-elevation myocardial infarction (STEMI) for primary p

94 right ventricular injury (RVI) complicating ST-elevation myocardial infarction (STEMI) have impaired

95 Myocardial Infarction (TIMI) risk score for ST-elevation myocardial infarction (STEMI) is a simple i

96 Percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is superior t

97 Reperfusion times for ST-elevation myocardial infarction (STEMI) occurring in

98 We analyzed GPVI-activated platelets from ST-elevation myocardial infarction (STEMI) patients and

99 to compare clinical and economic outcomes in ST-elevation myocardial infarction (STEMI) patients enco

100 In Europe, interhospital transfer of ST-elevation myocardial infarction (STEMI) patients for

101 Treatment times for ST-elevation myocardial infarction (STEMI) patients pres

102 This was a retrospective study of ST-elevation myocardial infarction (STEMI) patients who

103 sis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in

104 reduces the mortality rate of patients with ST-elevation myocardial infarction (STEMI) presenting wi

105 wer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fib

106 Patients with ST-elevation myocardial infarction (STEMI) requiring int

107 ased guidelines for staging of patients with ST-elevation myocardial infarction (STEMI) undergoing pe

108 and its impact on outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing pr

109 Patients (n = 315) with ST-elevation myocardial infarction (STEMI) were enrolled

110 ehospital triage protocols for patients with ST-elevation myocardial infarction (STEMI) will depend,

111 ore comorbidities, less often presented with ST-elevation myocardial infarction (STEMI), and had high

112 POSE OF REVIEW: For patients presenting with ST-elevation myocardial infarction (STEMI), primary perc

113 tide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI).

114 l to emergency cardiac care of patients with ST-elevation myocardial infarction (STEMI).

115 in mortality risk exists among patients with ST-elevation myocardial infarction (STEMI).

116 tion underlie acute thrombosis that leads to ST-elevation myocardial infarction (STEMI).

117 lvage and clinical outcome in patients after ST-elevation myocardial infarction (STEMI).

118 h increased mortality rates in patients with ST-elevation myocardial infarction (STEMI).

119 pports thrombosis and could possibly produce ST-elevation myocardial infarctions (STEMI).

120 hase I clinical trial in patients with first ST-elevation-myocardial infarction (STEMI), we combine f

121 hospital time intervals were associated with ST-elevation myocardial infarction system performance, d

122 /=15 minutes, prehospital ECG acquisition to ST-elevation myocardial infarction team notification </=

123 ificantly over time, with higher rates among ST-elevation myocardial infarction than non-ST-elevation

124 e aspirin reduces morbidity and mortality in ST-elevation myocardial infarction, the optimal dose is

125 Although well studied in ST-elevation myocardial infarction, the prognostic impor

126 es and had similar 2-year risks for death or ST-elevation myocardial infarction to bare-metal stents.

127 STEMI-RADIAL (ST Elevation Myocardial Infarction treated by RADIAL or

128 In patients receiving fibrinolysis for ST-elevation myocardial infarction, treatment with enoxa

129 us Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) trial evaluated whet

130 n Thrombus Containing Culprit Lesions in Non-ST-Elevation Myocardial Infarction) trial sought to asse

131 In unstable angina and non-ST elevation myocardial infarction, two major advances a

132 Unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) is a comm

133 Patients (n = 14, three women) with first ST-elevation myocardial infarction underwent cardiac mag

134 tent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) were sustained durin

135 In patients with ST-elevation myocardial infarction, when those with hemo

136 We randomly assigned 20,506 patients with ST-elevation myocardial infarction who were scheduled to

137 in patients with either ST elevation or non-ST elevation myocardial infarction with or without diabe

138 lysis of 1031 patients admitted with a first ST-elevation myocardial infarction with ischemic times b

139 Exclusion criteria were ST-elevation myocardial infarction within 24 h, being co